To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Hemophagocytic lymphohistiocytosis
Product highlightHemophagocytic lymphohistiocytosis (HLH) is an unusual syndrome characterized by fever, splenomegaly, jaundice, and the pathologic finding of hemophagocytosis. This is phagocytosis by macrophages of erythrocytes, leukocytes, platelets, and their precursors in bone marrow and other tissues.
HLH may be associated with malignant, genetic, or autoimmune diseases. It is also prominently linked with Epstein-Barr virus (EBV) infection, however it can also be associated with other viruses as well as fungal infections. Hyperproduction of cytokines, including interferon-g and tumor necrosis factor-a, by EBV-infected T lymphocytes may play a role in the pathogenesis of HLH. EBV-associated HLH may mimic T-cell lymphoma and is treated with cytotoxic chemotherapy. In contrast, hemophagocytic syndromes associated with nonviral pathogens often respond to treatment of the underlying infection. HLH comprises familial (primary) hemophagocytic lymphohistiocytosis (FHL) and secondary HLH (SHLH), both clinically characterized by the features described above, in particular fever, hepatosplenomegaly, and cytopenia. Familial formsFHL, an autosomal recessive disease, is invariably fatal when untreated. It is associated with defective triggering of apoptosis and reduced cytotoxic activity, resulting in a widespread accumulation of T lymphocytes and activated macrophages. There are four types, and each is associated with a specific gene: References
|
||||||||||||
| This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hemophagocytic_lymphohistiocytosis". A list of authors is available in Wikipedia. |
- Breakthrough in Cell Research: New Method for Drug Delivery - Overcoming the natural barrier of the cell wall
- HORIBA Europe GmbH - München, Alemanha
- Nuova dirigenza presso Ruland Engineering & Consulting GmbH - I fondatori cedono la gestione
- Nachschub für Krankheitserreger - Erreger der Legionärskrankheit zapfen Materialtransport von Immunzellen an
- TSKgel FCR-IIIA columns | Colonne per cromatografia di affinità | Tosoh



